Impact of MetaCalm on Stress of Healthy People With Acute Stress
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMetagenics, Inc.
About this trial
This Open-Label, Non-Randomized Clinical Study involving 280 participants who will undergo a total participation of 6 hours.
Eligibility criteria
Qualifiers
Providing written informed consent
Males and females of at least 18 years old
Obtaining a reference score of ≥ 30 on the STAI questionnaire (State-Trait Anxiety Inventory, short version, 10-item scale)
Disqualifiers
Being on anxiolytic and beta blocker treatment
Individuals who use illicit or recreational drugs
Having consumed adaptogen plants in one week prior to enrollment
Participating in another clinical trial
Trial design
Treatments tested in this trial
- 2 chewable tablets of MetaCalm
- 4 chewable tablets of MetaCalm
Treatment groups
280 Participants
are divided into 2 treatment groupsSponsors and collaborators
Metagenics, Inc.
Lead sponsor
Metagenics Europe
Collaborator
Source ClinicalTrials.gov